Novo Nordisk announced results from the REDEFINE-4 trial, which compared its investigational therapy CagriSema with tirzepatide. The study showed that people taking CagriSema lost about 23% of body weight over 84 weeks, compared with roughly 25.5% with tirzepatide. The trial did not meet its statistical goal of demonstrating non-inferiority on weight loss.
Much of the early discussion has focused on competition between drugs or the impact on company performance. From a patient perspective, however, the takeaway is different.
Both therapies produced substantial weight loss, reinforcing how far obesity treatment has progressed in recent years. Results at this level were once associated primarily with bariatric surgery, not medication.
CagriSema combines semaglutide with an amylin analogue, targeting appetite (hunger) and satiety (fullness) through complementary biological pathways. This difference in mechanism may offer another option for patients who do not tolerate or respond optimally to existing therapies.
For people living with obesity, treatment decisions rarely hinge on a single average number from a clinical trial. Factors such as tolerability, long-term adherence, comorbidities, access, and insurance coverage often determine which therapy works best in practice.
The REDEFINE-4 results therefore expand the conversation rather than narrow it.
Instead of asking which drug “won,” the more relevant question for patients and clinicians is which therapy helps a given individual achieve sustainable health improvements over time.
Industry Perspective
“We are pleased with the weight loss of 23% for CagriSema in this open-label trial. CagriSema has the potential to be the first GLP-1/amylin combination product for people living with obesity, demonstrating additive benefits beyond GLP-1 therapy alone.
We look forward to upcoming studies designed to assess the full weight-loss potential of CagriSema and continue advancing treatments that may offer greater health benefits for people living with obesity.”
— Martin Holst Lange, Novo Nordisk
Why “Not Non-Inferior” Doesn’t Mean “Not Useful”
Clinical trials sometimes test whether a new treatment performs at least as well as an existing one within a predefined margin. This is called a non-inferiority test.
If that statistical target isn’t met, it doesn't mean the treatment failed or lacks benefit. It means the study couldn't prove the new therapy fell within the comparison range defined before the trial began.
In REDEFINE-4, people taking CagriSema still experienced large average weight loss. The result simply shows that, in this particular study, the difference between treatments was greater than the margin researchers defined ahead of time.
For patients, the practical question remains the same:
Which treatment is safe, tolerable, accessible, and sustainable for the long term?
Sources
